Evaluation of the safety and tolerability of intravenous undiluted levetiracetam at a pediatric institution.
Lily PriceLisa GarritySarah R StiehlPublished in: Pharmacotherapy (2023)
Undiluted levetiracetam was not associated with an increased incidence of adverse effects compared to diluted levetiracetam in high-doses, up to 4500 mg given over 5 minutes in pediatric patients.